Literature DB >> 18199473

HPV genotyping in cervical cancer in Northern Thailand: adapting the linear array HPV assay for use on paraffin-embedded tissue.

Sumalee Siriaunkgul1, Supaporn Suwiwat, Jongkolnee Settakorn, Surapan Khunamornpong, Kobkul Tungsinmunkong, Anusorn Boonthum, Vipavadee Chaisuksunt, Suree Lekawanvijit, Jatupol Srisomboon, Paul S Thorner.   

Abstract

OBJECTIVES: The aims of this study were to determine the prevalence of HPV infection and distribution of HPV genotypes in Northern Thai women and thereby estimate the benefit of administering the HPV vaccine in the population.
METHODS: Formaldehyde-fixed, paraffin-embedded samples of invasive squamous cell carcinoma from 99 patients were tested for HPV genotypes using the Linear Array HPV Genotyping Test.
RESULTS: HPV was detected in 96/99 (96.9%) cases. Seventy-five (78.1%) cases were single infections and 21 (21.9%) multiple. HPV16 and HPV18 were the most common subtypes, detected in 62/96 (64.4%) cases. HPV52 and HPV58 infections were found in 17/96 (17.7%) cases. Co-infection always involved HPV16. The most common co-infection was HPV16 and 52 (7 cases) but never HPV16 and 18.
CONCLUSIONS: Although the prevalence of HPV infection in cervical cancer of Northern Thai women is comparable to the other regions worldwide, the distribution of HPV subtypes differs with lower frequencies of HPV16 and 18, and higher frequencies of HPV52 and 58. Moreover, multiple infections are common. The vaccine against HPV16 and HPV18 can be estimated to prevent approximately two thirds of the cervical cancer cases in Northern Thailand. Although designed for use on unfixed tissue, this study shows that the Linear Array HPV Genotyping Test can be successfully used for HPV genotyping on paraffin-embedded archival tissue. This methodology also provides a means for retrospective studies on serial samples for a greater understanding of HPV genotypes, co-infections, and relationship to cervical cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18199473     DOI: 10.1016/j.ygyno.2007.11.016

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  14 in total

1.  Human papillomavirus genotyping using archival vulval dysplastic or neoplastic biopsy tissues: comparison between the INNO-LiPA and linear array assays.

Authors:  Sarah E Tan; Suzanne M Garland; Alice R Rumbold; Sepehr N Tabrizi
Journal:  J Clin Microbiol       Date:  2010-02-24       Impact factor: 5.948

2.  The role of high-risk human papillomavirus infection in oral and oropharyngeal squamous cell carcinoma in non-smoking and non-drinking patients: a clinicopathological and molecular study of 46 cases.

Authors:  Jan Laco; Hana Vosmikova; Vendula Novakova; Petr Celakovsky; Helena Dolezalova; Lubos Tucek; Jana Nekvindova; Milan Vosmik; Eva Cermakova; Ales Ryska
Journal:  Virchows Arch       Date:  2011-01-11       Impact factor: 4.064

3.  Molecular genotyping of human papillomavirus l1 gene in low-risk and high-risk populations in Bangkok.

Authors:  Pornsawan Leaungwutiwong; Busara Bamrungsak; Akanitt Jittmittraphap; Pannamas Maneekan; Nathamon Kosoltanapiwat; Thareerat Kalambaheti; James F Kelley
Journal:  Sex Transm Dis       Date:  2015-04       Impact factor: 2.830

4.  Human papillomavirus infection and its possible correlation with p63 expression in cervical cancer in Japan, Mongolia, and Myanmar.

Authors:  Ulziibat Shirendeb; Yoshitaka Hishikawa; Shingo Moriyama; Ne Win; Minn Minn Myint Thu; Khin Swe Mar; Gerlee Khatanbaatar; Hideaki Masuzaki; Takehiko Koji
Journal:  Acta Histochem Cytochem       Date:  2009-12-22       Impact factor: 1.938

5.  Prognostic significance of human papillomavirus (HPV) status and expression of selected markers (HER2/neu, EGFR, VEGF, CD34, p63, p53 and Ki67/MIB-1) on outcome after (chemo-) radiotherapy in patients with squamous cell carcinoma of uterine cervix.

Authors:  Milan Vosmik; Jan Laco; Igor Sirak; Martin Beranek; Eva Hovorkova; Hana Vosmikova; Monika Drastikova; Miroslav Hodek; Zdenek Zoul; Karel Odrazka; Jiri Petera
Journal:  Pathol Oncol Res       Date:  2013-08-03       Impact factor: 3.201

6.  Genotypic distribution of human papillomavirus (HPV) and cervical cytology findings in 5906 Thai women undergoing cervical cancer screening programs.

Authors:  Nuttavut Kantathavorn; Chulabhorn Mahidol; Narongrit Sritana; Thaniya Sricharunrat; Natacha Phoolcharoen; Chirayu Auewarakul; Narongchai Teerayathanakul; Chantanee Taepisitpong; Siriporn Saeloo; Gaidganok Sornsamdang; Wandee Udomchaiprasertkul; Waraphorn Krongthong; Arpaporn Arnamwong
Journal:  Infect Agent Cancer       Date:  2015-03-02       Impact factor: 2.965

7.  Sequence-based approach for rapid identification of cross-clade CD8+ T-cell vaccine candidates from all high-risk HPV strains.

Authors:  Krishna P Singh; Neeraj Verma; Bashir A Akhoon; Vishal Bhatt; Shishir K Gupta; Shailendra K Gupta; Suchi Smita
Journal:  3 Biotech       Date:  2016-01-27       Impact factor: 2.406

8.  Improvement of DNA extraction for human papillomavirus genotyping from formalin-fixed paraffin-embedded tissues.

Authors:  Isabelle Cannavo; Céline Loubatier; Anne Chevallier; Valérie Giordanengo
Journal:  Biores Open Access       Date:  2012-12

9.  The Association Between Cervical Human Papillomavirus Infection and Subsequent HIV Acquisition in Tanzanian and Ugandan Women: A Nested Case-Control Study.

Authors:  Katherine E Gallagher; Kathy Baisley; Heiner Grosskurth; Andrew Vallely; Saidi Kapiga; Judith Vandepitte; Anatoli Kamali; Silvia De Sanjosé; John Changalucha; Richard Hayes; Deborah Watson-Jones
Journal:  J Infect Dis       Date:  2016-03-06       Impact factor: 5.226

10.  Genotyping for Human Papillomavirus (HPV) 16/18/52/58 Has a Higher Performance than HPV16/18 Genotyping in Triaging Women with Positive High-risk HPV Test in Northern Thailand.

Authors:  Surapan Khunamornpong; Jongkolnee Settakorn; Kornkanok Sukpan; Prapaporn Suprasert; Jatupol Srisomboon; Suthida Intaraphet; Sumalee Siriaunkgul
Journal:  PLoS One       Date:  2016-06-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.